ABVC BIOPHARMA, INC. Increase Decrease In Operating Lease Liability
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$79.61K.
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$75.11K.
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$197.50K, a 248.80% decline year-over-year.
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$95.92K.
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2025 was -$474.48K.
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2024 was -$168.90K.
- ABVC BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2023 was -$351.86K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$79.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$154.71K 10-Q · filed 2026-08-12 | -$352.21K derived: sum of 3 quarters · filed 2026-08-12 | -$448.13K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$75.11K 10-Q · filed 2026-05-18 | -$272.61K derived: sum of 2 quarters · filed 2026-05-18 | -$368.53K derived: sum of 3 quarters · filed 2026-05-18 | -$442.66K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$197.50K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-03 | -$293.42K derived: sum of 2 quarters · filed 2026-03-03 | -$367.55K derived: sum of 3 quarters · filed 2026-08-12 | -$474.48K 10-K · filed 2026-03-03 |
| 2025-09-30 | -$95.92K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-03 | -$170.05K derived: sum of 2 quarters · filed 2026-08-12 | -$276.98K 10-Q/A · filed 2026-03-03 | -$144.25K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$74.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$181.06K 10-Q · filed 2026-08-12 | -$48.33K derived: sum of 3 quarters · filed 2026-08-12 | -$147.68K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$106.93K 10-Q · filed 2026-05-18 | $25.80K derived: sum of 2 quarters · filed 2026-05-18 | -$73.54K derived: sum of 3 quarters · filed 2026-05-18 | -$174.56K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $132.73K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-03 | $33.39K derived: sum of 2 quarters · filed 2026-03-03 | -$67.64K derived: sum of 3 quarters · filed 2026-03-03 | -$168.90K 10-K · filed 2026-03-03 |
| 2024-09-30 | -$99.34K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-03 | -$200.36K derived: sum of 2 quarters · filed 2026-03-03 | -$301.62K 10-Q/A · filed 2026-03-03 | |
| 2024-06-30 | -$101.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$202.28K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$101.26K 10-Q · filed 2025-04-30 | |||
| 2023-12-31 | -$351.86K 10-K · filed 2025-04-15 |